Mistry et al., 1999 - Google Patents
Immunochemical detection of glyoxal DNA damageMistry et al., 1999
- Document ID
- 2523908797499244775
- Author
- Mistry N
- Evans M
- Griffiths H
- Kasai H
- Herbert K
- Lunec J
- Publication year
- Publication venue
- Free Radical Biology and Medicine
External Links
Snippet
The relevance of reactive oxygen species (ROS) in the pathogenesis of inflammatory diseases is widely documented. Immunochemical detection of ROS DNA adducts has been developed, however, recognition of glyoxal-DNA adducts has not previously been …
- 231100000277 DNA damage 0 title abstract description 28
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/5308—Immunoassay; Biospecific binding assay for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Body-Malapel et al. | The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases | |
Yarborough et al. | Immunoperoxidase detection of 8-hydroxydeoxyguanosine in aflatoxin B1-treated rat liver and human oral mucosal cells | |
Asare et al. | Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity | |
Lu et al. | Preparation of anti-pefloxacin antibody and development of an indirect competitive enzyme-linked immunosorbent assay for detection of pefloxacin residue in chicken liver | |
Akhter et al. | Acquired immunogenicity of calf thymus DNA and LDL modified by D-ribose: a comparative study | |
Shahab et al. | Acquired immunogenicity of human DNA damaged by N‐hydroxy‐N‐acetyl‐4‐aminobiphenyl | |
Huet et al. | Development of an ELISA screening test for nitroimidazoles in egg and chicken muscle | |
Asahi et al. | Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation | |
Lange et al. | Complement component C4-like protein in Atlantic cod (Gadus morhua L.)-Detection in ontogeny and identification of post-translational deimination in serum and extracellular vesicles | |
US20220400732A1 (en) | Anti-fructose therapy for colorectal and small intestine cancers | |
Mistry et al. | Immunochemical detection of glyoxal DNA damage | |
Sinha et al. | DNA cleavage and detection of DNA radicals formed from hydralazine and copper (II) by ESR and immuno-spin trapping | |
Dixit et al. | Immunological studies on peroxynitrite modified human DNA | |
Alzolibani | Preferential recognition of hydroxyl radical-modified superoxide dismutase by circulating autoantibodies in patients with alopecia areata | |
Habib et al. | Preferential recognition of peroxynitrite modified human DNA by circulating autoantibodies in cancer patients | |
JP4374248B2 (en) | Means for the treatment of atherosclerosis | |
Jia et al. | Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis | |
Mistry et al. | Novel monoclonal antibody recognition of oxidative DNA damage adduct, deoxycytidine-glyoxal | |
Hu et al. | Ornithine decarboxylase gene is overexpressed in colorectal carcinoma | |
Khan et al. | Preferential recognition of catechol-estrogen modified DNA by circulating autoantibodies in cancer patients | |
Goss et al. | Ischemia‐reperfusion of rat liver modulates hepcidin in vivo expression | |
Ohgaki et al. | DNA methylation in the digestive tract of F344 rats during chronic exposure to N-methyl-N-nitrosourea | |
US7504226B2 (en) | Methods relating to treatment of atherosclerosis | |
Khan et al. | Genotoxic effect and antigen binding characteristics of SLE auto-antibodies to peroxynitrite-modified human DNA | |
Oh et al. | Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA‐8159, an erectogenic, in rats |